Auckland Researchers Launch Clinical Trial to Investigate 5FU Chemotherapy Cardiotoxicity
• University of Auckland and Auckland City Hospital researchers initiate a clinical trial to study severe cardiac side effects of 5-fluorouracil (5FU), a widely-used chemotherapy drug affecting 5% of patients.
• The two-year study, funded by multiple organizations including the Gut Cancer Foundation, aims to identify risk factors and mechanisms behind 5FU-induced cardiotoxicity through comprehensive patient monitoring.
• Researchers will utilize Holter monitors, blood tests, and urine samples from cancer patients to understand drug metabolism patterns and develop predictive markers for adverse cardiac reactions.
© Copyright 2025. All Rights Reserved by MedPath